> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# Regulatory Review Period Determined for Tecentriq
- URL: https://www.fdaweb.com/regulatory-review-period-determined-for-tecentriq/
- Published: 2018-10-23T12:00:00.000Z
- Updated: 2026-09-15T00:40:09.000Z
- Author: David McFarland
- Tags: FDA Policy/General, #legacy-id-D5142643

*Federal Register* notice: FDA has determined for patent extension-related purposes the regulatory review period for Genentech’s Tecentriq (atezolizumab), indicated for treating patients with locally advanced or metastatic urothelial carcinoma who have disease progression during or following platinum-containing chemotherapy or who have disease progression within 12 months of neoadjuvant or adjuvant treatment with platinum-containing chemotherapy. The regulatory review period was determined to be 1,836 days, which includes 1,708 days during the testing phase and 128 days during the approval phase. To view the notice, click [here](https://www.gpo.gov/fdsys/pkg/FR-2018-10-22/pdf/2018-22957.pdf?ref=fdaweb.com).